Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study.

Effects of anti-human T lymphocyte immune globulins in patients: new or old. J Cell Mol Med (2016) 0.80

Impact of Immune-Modulatory Drugs on Regulatory T Cell. Transplantation (2016) 0.77

Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. J Nephropathol (2015) 0.75

A Proposal for Early Dosing Regimens in Heart Transplant Patients Receiving Thymoglobulin and Calcineurin Inhibition. Transplant Direct (2016) 0.75

Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract (2004) 8.06

Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med (2006) 4.79

Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13

Immunosuppressive drugs for kidney transplantation. N Engl J Med (2004) 4.09

A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant (2008) 2.81

Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation (2003) 2.48

Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22

OPTN/SRTR 2011 Annual Data Report: kidney. Am J Transplant (2013) 1.84

A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg (2008) 1.74

Ten-year outcome after rapid discontinuation of prednisone in adult primary kidney transplantation. Clin J Am Soc Nephrol (2012) 1.69

A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation (1999) 1.62

Regulatory T cells in kidney transplant recipients: the effect of induction immunosuppression therapy. Nephrol Dial Transplant (2011) 1.59

Immune reconstitution following rabbit antithymocyte globulin. Am J Transplant (2010) 1.54

The biology of recent thymic emigrants. Annu Rev Immunol (2012) 1.22

A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation (2003) 1.19

Lymphodepletion and homeostatic proliferation: implications for transplantation. Am J Transplant (2012) 1.19

Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation (2006) 1.11

The balance of deletion and regulation in allograft tolerance. Immunol Rev (2003) 1.11

Induction immunosuppression. Transplantation (2006) 1.10

Five-year follow up of thymoglobulin versus ATGAM induction in adult renal transplantation. Transplantation (2004) 1.07

A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation (2009) 1.01

A prospective, randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy: 10-year results. Transplantation (2008) 0.99

Association of antibody induction with short- and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol (2002) 0.96

In kidney transplant patients, alemtuzumab but not basiliximab/low-dose rabbit anti-thymocyte globulin induces B cell depletion and regeneration, which associates with a high incidence of de novo donor-specific anti-HLA antibody development. J Immunol (2013) 0.96

Long-term kinetic of T-lymphocyte subsets in kidney-transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies. Transplantation (2005) 0.93

Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int (2006) 0.91

Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days? J Transplant (2010) 0.90

Selection of induction therapy in kidney transplantation. Transpl Int (2012) 0.88

Prolonged, low-dose anti-thymocyte globulin, combined with CTLA4-Ig, promotes engraftment in a stringent transplant model. PLoS One (2013) 0.83

Antithymocyte globulin induction in living donor renal transplant recipients: final report of the TAILOR registry. Transplantation (2012) 0.83

Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol (2013) 0.79